THC-P
THC-P (tetrahydrocannabiphorol) is a cannabinoid that binds the CB1 receptor far more strongly than ordinary THC, making it substantially more potent, and is sold in hemp-derived products. Little is known about its safety, and the 2025 federal hemp law effective November 12, 2026 is expected to make most THC-P products federally illegal.
Overview
THC-P (tetrahydrocannabiphorol) is a cannabinoid identified in cannabis in trace amounts; commercial THC-P is generally synthesized. Its notable feature is potency: laboratory work suggests it binds the CB1 cannabinoid receptor many times more strongly than delta-9 THC, so small amounts can produce strong intoxication. It is sold in hemp-derived vapes, edibles, and blends, often alongside other novel cannabinoids.
Source: peer-reviewed literature (NIH/PMC); Congress.gov (CRS)
Chemistry & mechanism of action
THC-P activates the CB1 cannabinoid receptor, the same receptor behind the delta-9 THC high, but its longer molecular side chain lets it bind far more tightly — in vitro studies report affinity many times higher than delta-9 THC. This much stronger receptor binding is thought to explain its high potency and intense effects at small amounts, though human data are very limited.
Source: peer-reviewed literature (NIH/PMC)
Effects
Users report a strong, THC-like high — relaxation, euphoria, altered perception, heavy sedation — that can be considerably more intense than ordinary THC for a given amount, along with the usual dry mouth, red eyes, and impaired coordination. Because potency is high and products are inconsistently dosed, over-intoxication with anxiety, paranoia, and rapid heart rate is easy to reach.
Source: peer-reviewed literature (NIH/PMC)
Risks & harms
THC-P's core risk is its potency combined with how little is known about it. Because it binds CB1 far more strongly than ordinary THC, doses that seem small can produce intense, longer over-intoxication — pronounced anxiety, paranoia, rapid heart rate, disorientation, and in some cases fainting or vomiting — with edibles especially prone to delayed, severe effects. There is almost no human safety research, so long-term and higher-dose risks are essentially unknown, which is itself a hazard. As with other synthesized hemp cannabinoids, products are poorly regulated and frequently mislabeled, may contain manufacturing by-products, residual solvents, or other unlisted cannabinoids, and potency claims are unreliable. Accidental pediatric exposure from candy-like edibles is a serious danger. Keep away from children; if a child ingests a product, or anyone has severe distress, chest pain, fainting, or cannot be roused, call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.
Source: peer-reviewed literature (NIH/PMC); FDA; Congress.gov (CRS)
Legal status (US)
The legal status of THC-P is changing. Under the 2018 Farm Bill's delta-9-only threshold, hemp-derived THC-P has been sold in the same gray area as other novel hemp cannabinoids, with a patchwork of state restrictions. The 2025 federal law (P.L. 119-37) redefines 'hemp' using total THC and covers cannabinoids with THC-like effects and those synthesized outside the plant; effective November 12, 2026 it is expected to make most THC-P products federally illegal. Because this is mid-transition, with possible litigation and further legislation, verify current federal and state law before relying on any status. This page has not yet been medically reviewed.
Source: Congress.gov (CRS); US federal law (2018 Farm Bill; P.L. 119-37, eff. 2026-11-12); DEA
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With cannabis, anxiety or a racing heart usually pass with time. Sit somewhere calm, sip water, and rest — strong edibles in particular can take hours to ease.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 6453074PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- (6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-olPubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C23H34O2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CCCCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)OPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- OJTMRZHYTZMJKX-RTBURBONSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- thcp, 3-Heptyl-delta-1-thc, Tetrahydrocannabiphorol, THCP, Tetrahydrocannabinol-C7PubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA ↗ · retrieved 2026-06-18
Effects
- Effects
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Risks
- Risks
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Interactions
- Interactions
- Unknown — pending review
Dosage
Pending medical reviewer
